Strategy,

Strategy,Marketing,
Marketing,Sales
Sales
for
forRegenerative
RegenerativeTherapy
Therapy&&
Wound
WoundMangement
MangementininSaudi
Saudi
Arabia
Arabia

EMBOWERING HEALING
E M B O W E RI N G H E A L I N G

By: Adnan Hashim

Success is about being the best in
meeting and serving the needs of
our patients.

- ADNAN HASHIM
Agenda
Agenda
• Message
• Strategy
• Long Term Objectives
• Short Term Objectives
• Products Positioning
• Market Analysis
• Market Share & Target
• Market Positioning
• Sales Plan Guide Lines
• Action Plan Per Targeted Application
• Action Plan Targeted Products Vs Targeted Specialties VS targeted Sector
• Sales Target Per Item
• Conclusion
• Recommendations
 Message
Message
Restoring The Power To Heal
As to be different from the regular concepts that drive Health Care market, and to reflect the role play
of our medical solutions, to convey to each client, end-user, and patient, that we are helping their
bodies to restore the ability to regenerate and heal, by providing an efficient solutions to cure their
pain.
Market
Market
In a review for Saudi Arabia 2019 budget, the budget allocation for the health sector has grown by
8% to reach SR 172 billion in 2019, as compared to SR 159 billion in 2018.
As the increasing numbers of obesity, diabetes, infected wounds, amputations, and the need for
surgical procedures, placed a big burden on health care community and budget, the need for
regenerative medicine and biological products that present a solution for growing health problem.
With the effect of the pandemic the number of BKA has increased dramatically from 476 amputations
per month in 2016 to over 600 amputations monthly.

Also, the shape of our medical market did change and when became one buying entity “NUPCO” for
government and institution hospitals, it did became a price driven more that a quality. Which require a
changing strategy.

Source:
Source: Healthcare
Healthcare In
In Saudi
Saudi Arabia
Arabia Opportunities
Opportunities In
In The
The Sector,
Sector, May
May 2018,
2018, Knight
Knight Frank
Frank
 Market
MarketAnalysis
Analysis
This analysis is
General Surgery Annual Market Growth  
concerned with
2017 2018 2019 2020 2021 2022 2023
MOH Hospitals 93,066 110,784 122,298 135,009 149,040 164,530 181,630
number of
Institutional Hos. 40,759 46,580 54,678 64,184 75,342 88,441 103,816 surgeries for each
Privet Hospital 106,054 129,000 123,023 117,323 111,887 106,703 101,759 market sector to
determine, the
targeted specialty
General Surgery
in each sector.
200000
180000
160000
140000
120000
100000
80000
60000
40000
20000
0
2017 2018 2019 2020 2021 2022 2023

MOH Inst. Hospitals Privet Hospitals

Source:
Source: Ministry
Ministry of
of Health,
Health, yearly
yearly statistic
statistic book
book 2020
2020
 Market
MarketAnalysis
Analysis
ORTHO Surgery Annual Market Growth  
2017 2018 2019 2020 2021 2022 2023
MOH Hospitals 43,050 50,043 54,005 58,281 62,895 67,874 73,248
Institutional Hos. 21,299 23,567 24,578 25,632 26,732 27,879 29,075
Privet Hospital 54,982 54,437 62,104 70,851 80,830 92,214 105,201

Ortho Surgery
120000 Orthopedic
100000 Surgery:
80000
Best Growing
60000
sector is Privet
40000 Hospitals, then
20000 MOH Hospitals
0
2017 2018 2019 2020 2021 2022 2023

MOH Inst. Hospitals Privet Hospitals

Source:
Source: Ministry
Ministry of
of Health,
Health, yearly
yearly statistic
statistic book
book 2020
2020
 Market
MarketAnalysis
Analysis
Plastic Surgery Annual Market Growth  
2017 2018 2019 2020 2021 2022 2023
MOH Hospitals 8,624 11,204 13,016 15,121 17,567 20,408 23,708
Institutional Hos. 10,140 12,889 14,298 15,861 17,595 19,518 21,652
Privet Hospital 18,930 17,790 17,378 16,976 16,582 16,198 15,823

Plastic Surgery
25000 Plastic Surgery:
20000
Best Growing
15000 sector is MOH
Hospitals, then
10000 Institution
Hospitals
5000

0
2017 2018 2019 2020 2021 2022 2023

MOH Instit. Hospitals Privet Hospitals

Source:
Source: Ministry
Ministry of
of Health,
Health, yearly
yearly statistic
statistic book
book 2020
2020
 Market
MarketAnalysis
Analysis
Neuro Surgery Annual Market Growth  
2017 2018 2019 2020 2021 2022 2023
MOH Hospitals 6,423 8,376 8,483 8,591 8,701 8,812 8,925
Institutional Hos. 5,808 5,942 6,127 6,318 6,514 6,717 6,926
Privet Hospital 7,378 5,056 6,809 9,170 12,349 16,631 22,397

Neuro Surgery
25000 Neuro Surgery:
20000
Best Growing
15000 sector is Privet
Hospitals, then
10000
MOH Hospitals
5000

0
2017 2018 2019 2020 2021 2022 2023

MOH Instit. Hospitals Privet Hospitals

Source:
Source: Ministry
Ministry of
of Health,
Health, yearly
yearly statistic
statistic book
book 2020
2020
Organogenesis
OrganogenesisImpowering
ImpoweringHealing
Healing
Organogenesis products are classified as biological products, that
Nushield ® are concern with helping cells to immigrate and regenerate plus
Nushield ®
having living cells to multiplate and replace damaged cells to
Apligraf ® rebuild damaged tissue.
As competitors products claims that they stimulate the healing
Apligraf ® process, Organogenesis products are the only ones that contain
PuraPlyAM ® human living cells that are scientifically proven in building
PuraPlyAM ® human tissue.
With increasing number of amputations, infections, surgical
ReNu ® procedures for pain management, the demand for pain killers,
ReNu ® Organogenesis products come to reduce the need for those
painful treatments and heavy medications.
NuCell ®
NuCell ® For example TransCyte® as a substitute for Silver Sulfadiazine
cream, in addition it promote healing by supplying growth factors
Affinity ® for the wound.
Affinity ® A regular dressings line will be launched in Saudi Market early
2022, this line will cover all types of wound dressings requests
TransCyte ® from Silver, Collagen, Hydrocolloid, Calcium Alginate, etc.
TransCyte ®
Those are requested and needed on annual requests, which make
Wound Dressings Organogenesis the company the present a solution treatment for
Wound Dressings all types of wounds.
GluStitch
GluStitch
Bio-Genration
Bio-Genration

Proven Antimicrobial Medical Technology

bio–ARMA®, LLC. has developed innovative solutions for comprehensive
treatment and protection in the areas of medical devices and wound care,
infection control, and health & wellness.
bio-ARMA™ uses our novel bio-based antimicrobial compound embedded
directly into our materials to create products highly resistant to the growth
of harmful bacteria, viruses and fungus.
Active
ActiveImplants
Implants NuSerface®
NuSerface®
ChemVerion
ChemVerion ZorFlex®
ZorFlex®++FlexZorb®
FlexZorb®
Targeted
TargetedApplications
Applications
Plastic Surgery
Plastic Surgery
Wound Management
Wound Management

Orthopaedic Surgeries
Orthopaedic Surgeries

Sports Injuries
Sports Injuries
Targeted
TargetedMarket
MarketSegments
Segments
Privet & Insurance
Privet & Insurance
Pharmacies
Pharmacies

NUPCO
NUPCO

MODA
MODA
Red Current
Red Current
Strategy
Strategy

• Serving certain groups of customers and patients

• Developing a unique position and value for our products as solutions (Products Positioning)
• Distinguish our selves, products, and services from competitor.
• Developing a unique image for our division/company.
• Compete differently with others to become the leader in our market.
Long
LongTerm
TermObjectives
Objectives

• Position our products to be the patients and surgeon first choice in multiple surgical procedures and
pain / wound management.
• Active and aggressive marketing/sales team that will dominate the selected market.
• Achieving the sales of SR 100 million in the fourth year of operation.
Short
ShortTerm
TermObjectives
Objectives
• Complete SFDA registration
• Sign exclusive contracts for Gulf and Middle East
• Getting our market acceptance for our products
• Position our products to be the patients and surgeon first choice in multiple surgical procedures
including pain and wound management.
• Targeting privet sector hospitals and clinics.
• Targeting insurance companies for Allograft applications
• Establishing an active and aggressive marketing/sales team that will dominate the selected market.
• Be present in all network activities of targeted clients
• Secure cash sales channels with selected surgeons
• Conducting products launching event early 2022
• Achieving the sales of SR 10 million in the first year of operation.
 Sales
SalesPlan
Plan2022
2022
2022 Organogenesis

Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec. Total

Product Cost 50,320 465,380 684,300 425,460 988,480 130,000 317,260 142,000 997,640 513,500 701,800 812,000 6,228,140

Sales 83,927 753,135 1,173,518 754,400 1,599,041 293,250 527,781 310,500 1,629,504 848,700 1,213,768 1,271,900 10,459,423

G.P. 33,607 287,755 489,218 328,940 610,561 163,250 210,521 168,500 631,864 335,200 511,968 459,900 4,231,282

Sales Plan 2022 Organogenesis

1,600,000

1,200,000

800,000

400,000

-
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec.

Product Cost Sales G.P.

 Sales
SalesPlan
Plan2022
2022
2022 GluStitch

Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec. Total
Product Cost 41,223 36,302 86,531 40,782 37,468 61,748 29,378 30,226 33,728 36,056 24,150 9,068 466,660
Sales 237,676 208,955 498,784 235,060 215,740 355,983 169,395 174,053 194,408 207,978 139,150 52,095 2,689,275

G.P. 196,453 172,653 412,253 194,278 178,272 294,235 140,017 143,827 160,680 171,922 115,000 43,027 2,222,615

Sales PLan 2022 GluStitch

600,000
500,000
400,000
300,000
200,000
100,000
-
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec.

Product Cost Sales G.P.

 Sales
SalesPlan
Plan2023
2023
2023 Organogensis

Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec. Total
Product Cost 1,551,800 400,650
981,700 1,099,710
1,026,800 971,000 268,300 1,013,700 511,500 917,000 1,163,350 841,000 10,746,510

Sales 2,770,925 822,250

1,767,780
2,112,320 1,946,088 1,885,770 494,500 1,836,780 991,760 1,770,770 2,232,150 1,604,020 20,235,113

G.P. 857,700 314,350

555,500 737,090 665,450 668,800 161,700 583,500 350,900 622,800 777,650 553,800 6,849,240

Sales Plan 2023 Organogenesis

3,000,000
2,500,000
2,000,000
1,500,000
1,000,000
500,000
-
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec.

Product Cost Sales G.P.

 Sales
SalesPlan
Plan2023
2023
2023 GluStitch

Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec. Total
Product Cost 103,420 71,215 62,105 45,216
79,454 70,540 40,590 25,600 69,090 60,870 24,150 24,150 676,400

Sales 518,500 356,625 311,375 226,600 398,400

353,500
203,500 128,250 346,250
305,000 121,000 121,000 3,390,000

G.P. 415,080 285,410 249,270 181,384 318,946 282,960 162,910

102,650 277,160
244,130 96,850 96,850 2,713,600

Sales Plan 2023 GluStitch

600,000
500,000
400,000
300,000
200,000
100,000
-
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec.

Product Cost Sales G.P.

 Sales
SalesPlan
Plan2024
2024
Organogenesis 2024

Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec. Total

Product Cost 2,348,800 400,650 2,575,700 1,099,710 1,026,800 2,166,500 268,300 2,607,700 1,308,500 1,714,000 2,558,100 1,239,500 19,314,260

Sales 4,649,565 822,250 5,250,095 2,295,630 2,129,398 4,612,075 494,500 5,319,095 2,778,745 3,649,410 5,336,460 2,634,995 39,972,218

G.P.
1,694,300 314,350 1,989,600 896,490 824,850 1,844,000 161,700 2,017,600 1,107,800 1,459,400 2,082,300 1,051,800 15,444,190

Sales Plan 2024 Organogenesis

6,000,000
5,000,000
4,000,000
3,000,000
2,000,000
1,000,000
-
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec.

Product Cost Sales G.P.

 Sales
SalesPlan
Plan2024
2024
GluStitch 2024

Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec. Total

Product Cost 91,330 145,385 60,855 109,170 61,810 84,080 33,126 65,914 71,000 56,990 42,704
27,836
850,200

Sales 457,750 728,500 304,750 547,000 309,500 421,500 165,850 330,400 355,750 285,500 213,900
139,600
4,899,000

G.P.
366,420 583,115 243,895 437,830 247,690 337,420 132,724 264,486 284,750 228,510 171,196 111,764 3,409,800

Sales Plan 2024 GluStitch

800,000
600,000
400,000
200,000
-
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov. Dec.

Product Cost Sales G.P.

Business
BusinessStrategy
Strategy
Sales VS Cost

Operation Budget Product Cost Sales Net Profit

2021 180,534 305,452 631,600 295,614
2022 610,100 3,045,861 6,841,900 3,185,939
2023 1,046,760 Sales VS Cost
4,987,546 10,382,500 4,348,194

12,000,000
10,382,500
10,000,000

8,000,000
6,841,900

6,000,000 4,987,546

4,000,000 3,045,861

2,000,000
1,046,760
610,100 305,452 631,600
180,534
0
Operation Budget Product Cost Sales

2021 2022 2023

Business
BusinessStrategy
Strategy
Products Strategy

Nushield ReNu NuCel TranCyte Dressings

2021 20 190 0 0 0
2022 130 1,380 500 900 2,000
2023 850 1,670 1,150 1,200 2,300
Products Growth
2,500

2,000

1,500

1,000

500

0
Nushield ReNu NuCel TranCyte Dressings

2021 2022 2023

 Market
MarketPositioning
Positioning
Competition
Competition
• Only one product “Nushield“ we have a competitor for.
• Present treatment modalities in Sports medicine, orthopedic
surgery, Neuro Surgery, and Biofilm Management require
long time of treatment, multiple applications and patient
visits with no desired outcome, including courses of strong
medication that has heavy negative effect over the patients
health.

Patients
Patients
Due to the lack of effective therapy and desired outcome, patients
are facing the following:
• Increasing number of PKA
• Long treatment time and repeated clinic visits
• Increasing pain, and increasing medication
• Increasing cost of the conventional therapy
• Painful surgical procedures with no good results.
• Life style is changed, which patients have to change their
daily habits.
 Market
MarketPositioning
Positioning
H. I. and Insurance Companies
H. I. and Insurance Companies
• The poor outcome of conventional therapy.
• The continues complains of chronic wounds and pain.
• The risk of continues use of pain killers and antibiotics.
• Increasing the need for longer courses of physiotherapy.
• Increasing the cost of treatment on Insurance companies.

Organogenesis Products
Organogenesis Products
They are bioactive and acellular biomaterials products the takes advanced wound care, sports injuries,
orthopedics and spine surgeries to a new level of treatment.
Tissue repair and regeneration, are the needed healing processes for non healing injuries that other medical
products and surgical procedures can not provide.
Project
ProjectPlan
Plan
Sep Oct Nov Dec
1t W. 2d W. 3d W. 4h W. 1t W. 2d W. 3d W. 4h W. 1t W. 2d W. 3d W. 4h W. 1t W. 2d W. 3d W. 4h W.
MOU & NDA        
Contract        
Promotional Materials    
Samples        
Organogenesis KSA
Product Intr. & evaluation            
Product Request & quotation          
Purchase Orders & supply          
MDMA        

MOU & NDA      

Contract      
Promotional Materials    
Samples            
GluStitch
Product Intr. & evaluation        
Product Request & quotation            
Purchase Orders & supply          
MDMA            

MOU & NDA        

Contract        
Promotional Materials          
Samples        
Bio-Genration
Product Intr. & evaluation              
Product Request & quotation          
Purchase Orders & supply            
MDMA                
 pandemic

Sales
Sales Plan
Plan
Guide Lines
Guide Lines
Due to the pandemic COVID19 and the precaution procedures, the access to Institutional hospitals
and MOH hospitals is limited, which effect our business plan and sales focus directions.
This will place privet sector hospitals and medical insurance companies in first priority to achieve
sales targets, Institution hospitals and MOH comes in second priority according to sales team
relations.
As some of targeted products have a history in sales and were promoted before, Our team relations
with key person in those accounts will focus on reordering of those items in short time.

As sales team coverage for main cities and remote ones, our targeted sales and expansion will be
focused on main accounts in major cities.
Remote cities will be added value when sales are achieved.
 Action
ActionPlan
PlanPer
PerTargeted
TargetedApplication
Application
Patients with Chronic Wounds DFU & VLU
Patients with Chronic Wounds DFU & VLU
• Approaching Diabetic Departments and Centers. Obtaining feed back and evaluation in first 30
days
• Focusing on reordering of Apligraf to generate orders in short time. Reordering confirmation in 14
days.
• Approaching Wound Care teams in different targeted hospitals promoting and setting up clinical
Hospital
trials if needed. 60Department Product + Puraply
days. (Apligraf + Nushield EndUser
AM) Status Time Frame
Plastic Nushield Diaa Uthman Evaluation 60 Days
Sulima Habib Hospitals
Plastic Nushield Dawod Shikh Evaluation 60 Days
KAMC Wound Care Nushield Abdulkarim Blasi Order 60 Days
KFSH&RC Vscular Surgery Apligraf Sameer Qusair Reorder 30 Days
National Guards Foot Surgery Apligraf Jazwa Otaibi Reorder 60 Days
 Action
ActionPlan
PlanPer
PerTargeted
TargetedApplication
Application
Patients Of Sports Injuries
Patients Of Sports Injuries
• Approaching key surgeons in sports injuries to promote ReNu + Nushield. Evaluation and placing
orders should be in 60 days.
• Approaching Sports Clubs to promote ReNu Product. Creating awareness and demand should be in
90 days.
• Approaching Physiotherapy and rehab centers to promote ReNu, Creating awareness and demand
Hospital should be in 90 days.
Department Product EndUser Status Time Frame Contact Number
Humanitarian City Orthopedic Department Nushield + ReNu Dr. Khalil Rahman Evaluation 60 Days 554556728
Humanitarian City Orthopedic Department Nushield + ReNu Dr. Ezzat Evaluation 60 Days  
SANAD HOSPITAL Orthopedic Department Nushield + ReNu Dr. Monawer Evaluation 60 Days 531172704
SANAD HOSPITAL Orthopedic Department Nushield + ReNu Dr. Fouad Evaluation 60 Days 531172704
Abdul Rahman mshary Hos Orthopedic Department Nushield + ReNu Dr. Tariq Evaluation 60 Days 504418069
NMC Ishbilia Ortho Department Nushield + ReNu Dr. Saeed Ka'ban Evaluation 60 Days
Sulliman Habib ( alswedi ) Orthopedic Department Nushield + ReNu Dr. Adel Ghandor Evaluation 60 Days 590591400
Alhammadi Hospital Alnuzha Orthopedic Department Nushield + ReNu Dr. Moneer Khan Evaluation 60 Days  
Dallah Hospital Orthopedic Department Nushield + ReNu Prof. Abdulaziz Elshiban Evaluation 60 Days 555449122
Dallah Hospital Orthopedic Department Nushield + ReNu Dr. Essam Mohamed Evaluation 60 Days 568494935
Dallah Hospital Orthopedic Department Nushield + ReNu Dr. Mohamed Elharis Evaluation 60 Days 505418490
Dallah Hospital Orthopedic Department Nushield + ReNu Dr. Mustafa Elsanargi Evaluation 60 Days 50649324
Kingdom Hospital Orthopedic Department Nushield + ReNu Dr. Mohamed Sarwan Evaluation 60 Days
Specialized Medical Center Orthopedic Department Nushield + ReNu Dr. Modar Samarah Evaluation 60 Days 530408983
Specialized Medical Center Orthopedic Department Nushield + ReNu Dr. Bassam Sharif Evaluation 60 Days 557477508
Specialized Medical Center Orthopedic Department Nushield + ReNu Dr. Mousa Hasan Evaluation 60 Days xt.5445
 Action
ActionPlan
PlanPer
PerTargeted
TargetedApplication
Application
Patients Scheduled for Pain Relief Procedures
Patients Scheduled for Pain Relief Procedures
• Orthopedic surgeons concerned with Cartilage repair operations. Nushield need to be introduced,
trial and placing orders should be done in 60 days.
• Orthopedic surgeon concerned with lumbar decompression, lumbar discectomy, herniated disc,
and spinal fusion surgery, for using ReNu in their operations. Trial and placing orders should be
with 120 days.
• Adhesive capsulitis, Bursitis, Tendinosis, Partial rotator cuff tear, and epicondylitis, ReNu and
Hospital Nushield with be promoted, trial
Department cases and EndUser
Product orders should be placed
Statusin 120 days.
Time Frame Contact Number
KFSH OR Head Nushield Mr. Ali Elsewih Evaluation 60 Days 555498928
KFSH Orthopedic Dpt. Nushield Dr. Thamer Alhusinan Evaluation 60 Days  
Suliman Habib Hospitals Orthopedic Dpt. Nushield Dr. Salim Elzahrani Evaluation 60 Days 505474179
Suliman Habib Hospitals Orthopedic Dpt. Nushield Dr. Hussam Numer Evaluation 60 Days 565729010
Suliman Habib Hospitals Neuro Surgeon Nushield Dr. Abdullah Elnubhan Evaluation 60 Days  
Suliman Habib Hospitals Plastic Surgeon Nushield Dr. Dawod Elshikh Evaluation 60 Days  
Suliman Habib Hospitals Medical Director Nushield +ReNu Dr. Ali Elshuhri Evaluation 60 Days  
 KKUH Orthopedic Dpt. Nushield + ReNu   Dr. Abdelaziz Eloomar  Evaluation 60 Days  
 Aljazera Hospital Orthopedic Dpt. ReNu + Nushield Dr. Hassan Qannawi  Evaluation 60 Days  

 Humantarian City Orthopedic Dpt. ReNu Prof. Khalid Alrubeian  Evaluation 60 Days  
National Care Hospital Orthopedic Dpt. ReNu + Nushield Dr. Majdi Aljouda Evaluation 60 Days  

Aljazira Hospital Orthopedic Dept. ReNu Dr. Bashar Alhaj Evaluation 60 Days
 Action
ActionPlan
PlanPer
PerTargeted
TargetedApplication
Application
Cosmetic Procedures
Cosmetic Procedures

• Approaching plastic surgeons for the use of Nushield in facial surgeries reconstruction, nose
alignment, and burns. To avoid scar formation and healing without changing skin color, and for bone
healing. Trial and orders should be completed in 120 days.
Hospital Department Product EndUser Status Time Frame Contact Number
Clincs Center Plastic Surgery Nushield Dr. Taghreed Elhumsi Evaluation 60 Days  
Kadina Clinics Plastic Surgery Nushield Dr. Abdulmuhsen Ellazam Evaluation 60 Days  
Dallah Hospital Plastic Surgery Nushield Dr. Adnan Julidan Evaluation 60 Days  

Specialized Clinics Plastic Surgery +  

Orthopedic Nushield + ReNu DR. Abdulelah Elbasas Evaluation 60 Days
Prince Mohamed Hospital Plastic Surgery Nushield Dr. Maher Evaluation 60 Days  
Prince Mohamed Hospital Plastic Surgery Nushield Dr. Ahmed Almuqaied Evaluation 60 Days  
Security Forces Hospital Plastic Surgery Nushield Dr. Mohamed Qahtan Evaluation 60 Days
Consulting Clinics Plastic Surgery Nushield Ms. Badia Evaluation 60 Days
Conclusion
Conclusion
• Organogenesis products are used in four hospital departments, Ortho, Sports, Plastic, and Wound
Management.
• Competition is narrow, similar products are very rear in the market.
• Product knowledge need to be build for surgeon and patients on parallel level.
• The market has great potential for such products.
Recommendations
Recommendations
• Placing the team for training
• Using present contacts to generate the orders of Apligraf
• Placing the sales and marketing plane in to action.
• Prepare the product knowledge and samples in for the market as planned.
• Plan a webinar with key surgeons for Wounds and another one for orthopedic surgeons.
Thank
ThankYou
You